Abstract Library

#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs

Introduction: NETs overexpress somatostatin receptors (SSTRs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cives M

Authors: Mandriani B, Cives M, Pelle' E, Quaresmini D, Ramello M,

Keywords: CAR T cells, adoptive cellular immunotherapy, NETs,

#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?

Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liberini V

Authors: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F,

Keywords: radiomic, PRRT, NET, SSTR-RADS, NETPET grade, RECIST 1.1 criteria, 68Ga-DOTATOC PET/CT, tumor/spleen ratio, radiomic analysis of 68Ga-DOTATOC PET/CT, radiomic features,

#1707 Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?

Introduction: Small intestinal neuroendocrine tumors (siNETs) are rare tumors that raise several clinical and therapeutic challenges. Current treatments are not efficient, in part because of a poor understanding of their mechanisms of progression. We recently highlighted some axon guidance molecules (AGMs) that might be implicated in the progression of siNETs. Among them, we are currently focusing our efforts on the semaphorin 3F receptor neuropilin-2 (NRP2).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Bollard J, Massoma P, Patte C, Carbonnaux M, Vercherat C,

Keywords: siNETs, progression, NRP2 ,

#1325 Detection within a Neuroendocrine Tumor of High Levels of B-Lymphocyte Stimulator (BLyS) Correlates with a Greater Disease Severity

Introduction: .

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Grimaldi F, Motta C, Cipri C, Tonelli V, Pistis C,

Keywords: Tumor marker,

#1166 mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis

Introduction: Pancreatic neuroendocrine tumors (pNETs) are generally chemoresistants probably due to low proliferation rate and defects in apoptotic pathway. Targeted therapies are new encouraging options for pNETs however; clinical trials show limited objective response. Combination of chemotherapy and targeted therapy could be a new solution in therapeutic care. Streptozotocin (STZ) is the 1st line of therapy for unresectable pNETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Vercherat C

Authors: Vercherat C, Walter T, Massoma-Peh P, Bollard J, Lacheretz-Bernigaud A,

Keywords: neuroendocrine, therapy, Streptozotocin, mTOR pathway, combination, pre-clinical study,